Study type

Study topic

Human medicinal product
DiseaseĀ /health condition

Study type

Non-interventional study

Scope of the study

Drug utilisation

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Name of medicine, other

Sensipar

Medical condition to be studied

Hyperparathyroidism secondary
Population studied

Short description of the study population

Adult patients (18 years and older) with end-stage renal disease (ESRD) who received center based hemodialysis at a DaVita facility in the United States and had Medicare as their primary insurer between 2006 and 2010.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Renal impaired

Estimated number of subjects

44000
Study design details

Main study objective

To describe risk factors for first discontinuation of cinacalcet among center-based hemodialysis patients,To describe factors with reinitiation of cinacalcet among center-based hemiodialysis patients,To describe the trajectory of parathyroid hormone, calcium, and phosphorus laboratory values following the discontinuation of cinacalcet by center-based hemodialysis patients.

Outcomes

Probability of first cinacalcet discontinuation.Probability of cinacalcet reinitiation follwoing the first discontinuation of period.Mean values of parathyroid hormone, calcium and phosphorus.

Data analysis plan

Logistic regression will be used to estimate the probability of reinitiating or not reinitiating cinacalcet given the various convariates determined at the end of the previous 30-day interval and identify predicators of discontinuation and reinitiation. Laboratory values following of discontinuation as a function of time will be modeled using smoothing splines.
Documents
Study results
English (1.15 MB - PDF)View document